Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.60 |
| ▸ | FAAH | O00519 | 2/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | AOC2 | O75106 | 3/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 8/20 | 0.50 |
| ▸ | GSK3A | P49840 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749977 | 0.80 | AOC2 (0.59) | MGLLFAAHAOC2AOC3 | |
| SCHEMBL11796135 | 0.80 | AOC2 (0.66) | AOC2AOC3CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL146412 | 0.78 | MGLL (1.00) | MGLLFAAHPTGS1PTGS2GSK3A | |
| SCHEMBL965837 | 0.74 | LMNA (0.59) | AOC2 | |
| SCHEMBL8738193 | 0.72 | GSK3A (0.46) | MGLLFAAHPTGS1PTGS2GSK3A | |
| SCHEMBL2492150 | 0.72 | CA2 (0.59) | AOC2AOC3CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15704375 | 0.72 | MGLL (0.78) | MGLLFAAHPTGS1PTGS2GSK3A | |
| SCHEMBL5752289 | 0.72 | AOC2 (0.58) | AOC2AOC3CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4804503 | 0.72 | MGLL (0.78) | MGLLFAAHPTGS1PTGS2GSK3A | |
| SCHEMBL27633225 | 0.72 | AOC2 (0.58) | AOC2AOC3CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | MGLL 1067/4885FAAH 1337/4885PTGS1 1127/4885 |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | MGLL 1067/4885FAAH 1337/4885PTGS1 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.